Novo Nordisk CSO Outlines Obesity R&D Strategy, Calls Condition "Ticking Time Bomb"
Executive Summary
Novo Nordisk' obesity pipeline consists of projects addressing both appetite reduction and energy expenditure, with GLP-1 semaglutide topping the list, its CSO says in an interview with Scrip.
You may also be interested in...
US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone
The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Novo Nordisk, Embark Seek Obesity Drugs That Boost Body's Energy Use
Danish duo enter pact to discover novel therapeutics for obesity and related metabolic diseases using mechanisms that increase the body's expenditure of energy.